Compare AbbVie Inc (ABBV) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Global X Lithium & Battery Tech ETF — how do they compare? AbbVie Inc trades at $248.22 (market cap $441.94B), while Global X Lithium & Battery Tech ETF trades at $75.34. The key difference: AbbVie Inc pays a 2.77% dividend while Global X Lithium & Battery Tech ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | LIT | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $263.58 | $91.62 |
52-Week Low | $197.38 | $44.96 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
LIT trades at $75.21, up 0.63% with a bullish technical signal supported by moving averages. The stock has doubled over the past year, driven by strong momentum in energy storage, semiconductors, and electric vehicles. Recent news highlights global EV sales growth and China's ambitious 30% NEV fleet target by 2030, providing positive sector tailwinds. However, key financial ratios remain undisclosed in current data.
The outlook remains positive given sector catalysts in EVs and energy storage, though RSI levels suggest potential near-term overbought conditions. Investment opportunities center on lithium market inflection and semiconductor demand, while risks include competitive pressures and reliance on Chinese EV policy developments. The stock's 125% return from last year's low indicates strong momentum but warrants caution at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
